FDA has promoted Kathleen Uhl from acting to permanent director of its Office of Generic Drugs (OGD), according to RAPS. Uhl had served as acting director of OGD since July 2012, when she replaced Greg Geba. In that capacity, Uhl oversaw the agency’s implementation of the Generic User Fee Act, which RAPS credits as “decreasing application backlogs and increasing FDA inspections of foreign generic drug facilities.”
FDA appoints Office of Generic Drugs director
FDA has named Kathleen Uhl as permanent director of the Office of Generic Drugs.
